Trial Profile
A Double-blind, Triple Dummy, Placebo-controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow During a Public Speaking Test in Subjects Affected by Social Phobia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Vestipitant (Primary) ; Paroxetine
- Indications Social phobia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 12 Oct 2006 New trial record.